Genetische Aspekte von Schlafstörungen

PETER YOUNG

doi:10.1055/s-0038-1626148

Schlaf, Table of Contents

Schlaf 2015; 04(04): 193-198
DOI: 10.1055/s-0038-1626148

Review

Schattauer GmbH

Genetische Aspekte von Schlafstörungen

PETER YOUNG

¹Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen, Münster, Email: Peter.Young@ukmuenster.de

› Author Affiliations

Abstract

Für viele internistische, neurologische und pädiatrische Erkrankungen ist mittlerweile der Einfluss von Genen und mutierten Genen ausreichend geklärt. Für Schlafstörungen werden weiterhin ursächlich häufig sehr viel eher äußere Einflüsse (Licht, Temperatur, soziale Belastung, Lebensalter, etc.) angeführt.

Full Text

References

Literatur
1 Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004; 24: 249-259.
2 Winkelmann J, Polo O, Provini F. et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord 2007; 22 (Suppl. 18) S449-458.
3 Montplaisir J, Godbout R, Boghen D, DeChamplain J, Young SN, Lapierre G. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985; 35: 130-134.
4 Winkelmann J, Czamara D, Schormair B. et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011; 7: e1002171.
5 Winkelmann J, Lichtner P, Putz B. et al. Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord 2006; 21: 28-33.
6 Schulte EC, Knauf F, Kemlink D. et al. Variant screening of the coding regions of MEIS1 in patients with restless legs syndrome. Neurology 2011; 76: 1106-1108.
7 Spieler D, Kaffe M, Knauf F. et al. Restless legs syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon. Genome Res 2014; 24: 592-603.
8 Hublin C, Kaprio J, Partinen M, Heikkila K, Koskenvuo M. Prevalence and genetics of sleepwalking: a population-based twin study. Neurology 1997; 48: 177-181.
9 Petit D, Pennestri MH, Paquet J. et al. Childhood Sleepwalking and Sleep Terrors: A Longitudinal Study of Prevalence and Familial Aggregation. JAMA Pediatr 2015; 169: 653-658.
10 Kales A, Soldatos CR, Bixler EO. et al. Hereditary factors in sleepwalking and night terrors. Br J Psychiatry 1980; 137: 111-118.
11 Lecendreux M, Bassetti C, Dauvilliers Y, Mayer G, Neidhart E, Tafti M. HLA and genetic susceptibility to sleepwalking. Mol Psychiatry 2003; 8: 114-117.
12 Schenck CH, Boyd JL, Mahowald MW. A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep 1997; 20: 972-981.
13 Howell MJ. Parasomnias: an updated review. Neurotherapeutics 2012; 9: 753-775.
14 Hublin C, Kaprio J. Genetic aspects and genetic epidemiology of parasomnias. Sleep Med Rev 2003; 7: 413-421.
15 Hublin C, Kaprio J, Partinen M, Koskenvu M. Parasomnias: co-occurrence and genetics. Psychiatr Genet 2001; 11: 65-70.
16 Mahowald MW, Schenck CH. The REM sleep behavior disorder odyssey. Sleep Med Rev 2009; 13: 381-384.
17 Boeve BF, Silber MH, Parisi JE. et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61: 40-45.
18 Schulte EC, Ellwanger DC, Dihanich S. et al. Rare variants in LRRK1 and Parkinson’s disease. Neurogenetics 2014; 15: 49-57.
19 Onofrj M, Luciano AL, Iacono D. et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson’s disease. Mov Disord 2003; 18: 337-340.
20 Aldrich MS. Narcolepsy. N Engl J Med 1990; 323: 389-394.
21 Leschziner G. Narcolepsy: a clinical review. Pract Neurol 2014; 14: 323-331.
22 van der Heide A, Verduijn W, Haasnoot GW, Drabbels JJ, Lammers GJ, Claas FH. HLA dosage effect in narcolepsy with cataplexy. Immunogenetics 2015; 67: 1-6.
23 Hor H, Kutalik Z, Dauvilliers Y. et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010; 42: 786-789.
24 Miyagawa T, Kawashima M, Nishida N. et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008; 40: 1324-1328.
25 Redline S, Tishler PV. The genetics of sleep apnea. Sleep Med Rev 2000; 4: 583-602.
26 Redline S, Tosteson T, Tishler PV, Carskadon MA, Millman RP. Studies in the genetics of obstructive sleep apnea. Familial aggregation of symptoms associated with sleep-related breathing disturbances. Am Rev Respir Dis 1992; 145: 440-444.
27 Boentert M, Knop K, Schuhmacher C, Gess B, Okegwo A, Young P. Sleep disorders in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry 2014; 85: 319-325.
28 Gozal D, Capdevila OS, Kheirandish-Gozal L, Crabtree VM. APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. Neurology 2007; 69: 243-249.
29 Trochet D, O’Brien LM, Gozal D. et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet 2005; 76: 421-426.
30 Sack RL, Auckley D, Auger RR. et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30: 1484-1501.
31 Toh KL. Basic science review on circadian rhythm biology and circadian sleep disorders. Ann Acad Med Singapore 2008; 37: 662-668.
32 Toh KL, Jones CR, He Y. et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001; 291: 1040-1043.
33 Jafarpour A. et al. Typ-1-Narkolepsie. Schlaf 2015; 4: 147-153.